The woman first sought care at an informal community facility after an acute stressful life event was followed by a severe, new holocranial pressure-type headache on February 20, 2025. Unlike her previous episodic migraines, the pain was continuous and did not respond to non-steroidal anti-inflammatory drugs or a combination of acetaminophen, caffeine and dihydroergotamine. On February 26, an unregulated lay practitioner performed a cervical manipulation without a documented prior neurological examination. Seconds afterward, the patient lost consciousness for about three minutes and then recovered spontaneously. On awakening, she had right-sided hemiparesis, right central facial palsy and motor aphasia, with a recorded blood pressure of 140/100 mmHg.

She was transferred to a tertiary care center, where emergency non-contrast computed tomography showed neither acute hemorrhage nor an established territorial infarction. Magnetic resonance imaging performed two days later identified an acute ischemic lesion in the left pons. The lesion was hyperintense on T2-FLAIR and diffusion-weighted imaging, with corresponding attenuation on the apparent diffusion coefficient map, supporting an acute brainstem infarction. Because the initial scan did not show hemorrhage and the patient arrived beyond the therapeutic window for reperfusion, treating clinicians began aspirin at 81 mg daily and initiated neurological rehabilitation. Her aphasia resolved progressively and her hemiparesis improved partly, although a focal neurological deficit remained.

Contrast-enhanced CT angiography of the head and neck, performed on day nine, showed a complete filling defect through the V1 to V3 segments of the right vertebral artery and a thread-like distal V4 segment described as a “string sign.” The basilar artery was fully opacified, while the left vertebral artery remained patent with normal contrast filling. The images did not directly show classic pathognomonic features such as an intimal flap, double lumen or pseudoaneurysm. Nevertheless, the clinicians considered the segmental occlusion and distal string sign highly compatible with vertebral artery dissection in a young patient without atherosclerotic disease or identified thrombophilia. Primary thrombosis and arterial hypoplasia remained alternatives in the differential diagnosis.

Distinguishing dissection from other causes matters because a cervical artery dissection can create an intramural thrombus that embolizes into the posterior circulation, producing infarction. The report notes that thromboembolism is the most common pathophysiological mechanism in ischemic stroke caused by dissection and is associated with neuroimaging evidence of thrombus formation. Dissections may arise spontaneously, and reported associations include connective-tissue disorders such as fibromuscular dysplasia, Ehlers-Danlos syndrome, Marfan syndrome and Loeys-Dietz syndrome, as well as vascular anatomical variation, migraine, recent infection, hyperhomocysteinemia, oral contraceptive use and other conditions. The clinical literature does not establish many of those factors as independent risk factors, however.

The case is especially notable because the manipulation followed a prolonged, atypical headache. Severe localized or holocranial headache and neck pain can precede overt ischemic symptoms in cervical artery dissection, apparently reflecting nociceptive activation within the injured arterial wall. In this patient, dissection or subclinical thrombosis might therefore have been underway before the practitioner applied the high-velocity maneuver. The procedure could have aggravated an existing vascular tear or dislodged thrombus into the basilar circulation, but the case cannot distinguish these possibilities or establish a single mechanism.

Broader evidence also cautions against treating temporal sequence as definitive causation. A 2013 systematic review by Wynd and colleagues assessed cervical artery dissection associated with cervical manipulation therapy using Bradford Hill criteria. About 70% of the reported dissections involved the vertebral or carotid arteries. Among 707 cases that specified stroke type, 706 were ischemic, and the brainstem was the most common infarct location among the 32 cases reporting anatomical detail. A nationwide study of more than 5,000 cervical artery dissection cases examined by Whedon and colleagues in 2023 found that people evaluated for prodromal neck pain or headache were more likely subsequently to receive a dissection diagnosis than people receiving spinal manipulation. The authors interpreted much of the manipulation-dissection association as non-causal, attributing it to patients seeking treatment for symptoms of an impending or active dissection, and emphasized that the absolute risk of vertebral artery dissection after manipulation is extremely low.

Diagnostic assessment can be difficult because the sensitivity of imaging methods varies. Head and neck CT angiography or magnetic resonance angiography may be used alongside a neurological evaluation, and the report notes that CT angiography has shown superior diagnostic accuracy for vertebral artery dissection in particular. In this case, the initial CT and MRI sequence established the pontine infarct, while CTA nine days later documented the right vertebral artery occlusion. The delayed timing of vascular imaging reflects institutional logistics and the absence of baseline angiography, but it also means the report cannot directly show the artery’s condition before the event. The authors considered vertebral artery dissection the most compatible diagnosis while acknowledging that the defining structural signs were not visualized.

The report is a retrospective, single-case account with several important limitations. A close temporal relationship and compatible imaging findings do not establish that manipulation caused the occlusion or infarction. Oral contraceptive use, migraine and acute psychological stress could have contributed to the clinical setting, while the absence of pre-event vascular imaging prevents the investigators from definitively excluding arterial hypoplasia or vascular dysplasia. Moreover, much of the evidence linking cervical manipulation therapy to vertebrobasilar stroke consists of case reports, case series and expert opinion. The report therefore supports vigilance and careful documentation rather than a conclusion that manipulation routinely causes stroke. Its central message is that severe, atypical or refractory headache preceding manual neck treatment may warrant a different diagnostic approach, particularly when sudden neurological symptoms emerge during or immediately afterward.

Subject of Research: A case report linking cervical manipulation with vertebral artery occlusion and pontine ischemic stroke

Article Title: Ischemic Stroke Associated With Vertebral Artery Occlusion Following Cervical Spine Manipulation in a Young Woman With Underlying Vascular Risk Factors: A Case Report

Article References: González‐Delatorre, A., Alvarado‐Velásquez, J., Ruiz‐Alayón, B., López‐Sánchez, C., & Ayala‐Hernández, J. (2026). Ischemic Stroke Associated With Vertebral Artery Occlusion Following Cervical Spine Manipulation in a Young Woman With Underlying Vascular Risk Factors: A Case Report. Clinical Case Reports, 14(10), Article e73772. https://doi.org/10.1002/ccr3.73772

Image Credits: AI Generated

DOI: 10.1002/ccr3.73772

Keywords: cervical manipulation, vertebral artery occlusion, pontine stroke, arterial dissection, case report, oral contraceptives, migraine, head and neck CTA, cerebrovascular disease, Ischemic, Stroke, Associated

The research, published in Physiological Reports, examined 49 healthy females aged 18 to 45 years, dividing them into three groups: those with natural menstrual cycles, those taking second-generation combined oral contraceptive pills, and those on third-generation formulations. The findings were striking. Fasting glucose concentrations were approximately 10 percent higher in second-generation pill users and roughly 12.5 percent higher in third-generation users compared to naturally cycling women. Even more dramatic, fasting triglycerides were elevated by 56 to 70 percent in pill users relative to their naturally cycling counterparts. These are not trivial differences for a population of young, healthy, normal-weight women.

What makes this study particularly valuable is the rigor with which the researchers controlled for variables that have plagued previous investigations. Earlier studies on oral contraceptives and metabolism have produced wildly inconsistent results—some reporting benefits, others harm, and still others no effect at all. The McMaster team identified several reasons for this confusion. Many prior studies failed to account for the phase of the pill cycle or menstrual cycle at which blood samples were drawn. Others compared short-term users to long-term users without accounting for the body’s adaptation over time. And critically, several lacked a proper control group of naturally cycling individuals, making it impossible to disentangle the effects of the pill from natural hormonal variation.

To address these methodological gaps, the researchers implemented what they describe as rigorous temporal controls. Participants attended two laboratory visits timed to coincide with their low-hormone and high-hormone phases. For naturally cycling women, this meant the early follicular phase (days 3 to 7) and the mid-luteal phase (approximately 7 days after ovulation, confirmed with at-home ovulation kits). For pill users, visits were scheduled during the placebo week and during the third week of active pill use—the highest hormone week for those on triphasic formulations. Blood samples were collected in a fasted state at consistent times of day, and all participants underwent dual-energy X-ray absorptiometry (DXA) scans to assess body composition with precision.

The results extended beyond glucose and triglycerides. The researchers also found that appendicular lean mass index—a measure of skeletal muscle mass in the arms and legs normalized to height—was approximately 10 percent lower in both pill-user groups compared to naturally cycling women. However, when lean mass was expressed as a percentage of total body mass rather than height, this difference disappeared, suggesting that the naturally cycling group may simply have had larger and leaner lower bodies rather than a fundamentally different muscle distribution. Leg lean mass also trended toward being lower in pill users, though this did not reach statistical significance.

One of the most intriguing findings emerged from an exploratory sub-analysis. When all participants were pooled into a single group, the researchers observed a moderate negative correlation between appendicular lean mass index and fasting glucose concentrations—but only during the high-hormone phase. This suggests that skeletal muscle mass may play a more active role in glucose regulation during certain hormonal contexts than previously appreciated. Skeletal muscle is responsible for as much as 75 percent of glucose uptake from the bloodstream following a carbohydrate-containing meal, making it a critical player in metabolic health. Previous research has shown that lower muscle mass predicts impaired fasting glucose in elderly women, and the current findings hint that this relationship may extend to younger populations under specific hormonal conditions.

The mechanisms behind these metabolic differences likely involve the synthetic estrogen ethinyl estradiol, which is contained in both second- and third-generation oral contraceptives. Endogenous 17β estradiol—the naturally produced form of estrogen—plays a beneficial role in energy metabolism. It facilitates insulin secretion, stimulates glucose uptake from the bloodstream, reduces hepatic glucose release, promotes the shift from lipid storage to lipid oxidation, and lowers circulating triglyceride concentrations. Crucially, chronic exposure to ethinyl estradiol dramatically suppresses the body’s own estrogen production. The researchers previously confirmed that circulating 17β estradiol concentrations were significantly lower in both pill-user groups compared to naturally cycling women during the high-hormone phase. It is therefore plausible that pill users simply had less natural estrogen available to perform these metabolic protective functions.

The divergence between pill generations adds another layer of complexity. Third-generation users had approximately 40 percent higher HDL cholesterol concentrations compared to second-generation users, and there was a trend toward a lower total cholesterol to HDL ratio in the third-generation group. This difference likely relates to the type of progestin used in each formulation. Second-generation pills contain androgenic progestins that may antagonize the lipid effects of ethinyl estradiol, while the less androgenic progestins in third-generation pills may instead enhance them. This finding underscores the importance of distinguishing not just between pill users and non-users, but between different generations and formulations of the pill itself.

Importantly, the researchers caution that the magnitude of these differences, while statistically significant, remains modest in absolute terms. Average fasting glucose in all three groups remained well below the clinical threshold for concern, and only one participant across the entire study met the criteria for metabolic syndrome. For young, healthy, normal-weight women, the pill is unlikely to meaningfully increase the risk of developing metabolic disease. However, the researchers note that these subtle shifts could become clinically relevant for individuals with preexisting risk factors. A woman whose fasting glucose sits at 5.1 millimoles per liter before starting the pill, for example, could cross the threshold into the elevated range with the kind of increase observed in this study.

As metabolic syndrome rates continue to rise worldwide—particularly among women aged 18 to 45, the demographic most likely to use oral contraceptives—these findings carry significant public health implications. They also suggest that researchers may need to reconsider how they design studies involving female participants. Rather than excluding pill users to control for hormonal variability, the authors propose that expanding eligibility criteria to include both naturally cycling women and pill users could actually increase female participation in physiological research while improving the relevance and generalizability of the results. Future work, they note, should also examine how newer long-acting hormonal contraceptives, such as hormonal intrauterine devices, influence metabolism and body composition, as their popularity has surged over the past decade.

Subject of Research: The effects of combined oral contraceptive pills on fasting glucose, lipid metabolism, and body composition in young healthy females

Article Title: Elevated fasting glucose and triglycerides in combined oral contraceptive users compared to naturally cycling females

Article References: Karaguesian, C., Williams, J. S., MacDonald, M. J., & Bell, K. E. (2026). Elevated fasting glucose and triglycerides in combined oral contraceptive users compared to naturally cycling females. Physiological Reports, 14(19), Article e71135. https://doi.org/10.14814/phy2.71135

Image Credits: AI Generated

DOI: 10.14814/phy2.71135

Keywords: oral contraceptives, fasting glucose, triglycerides, metabolic syndrome, estrogen, body composition, HDL cholesterol, insulin resistance, menstrual cycle, women's health, DXA, skeletal muscle

NETosis is a spectacular and violent form of cell death. When a neutrophil is activated, it decondenses its own nucleus, mixes its DNA with cytoplasmic and granule proteins, and casts the whole tangle outward as a web-like structure that can snare and neutralize pathogens. The process is a cornerstone of innate immunity, but it has a dark side. In rheumatoid arthritis, proteins externalized during NETosis can become citrullinated, sparking the generation of anti-citrullinated protein antibodies, or ACPA, the hallmark autoantibodies of the disease. NETs correlate with disease activity in RA patients, and in systemic lupus erythematosus, a relative inability to degrade NETs has been linked to a higher incidence of lupus nephritis, one of the most serious complications of the disease.

What makes the new findings especially provocative is the demographic backdrop. Autoimmune diseases in which NETs are implicated strike women far more often than men, and the skew is most extreme during the premenopausal years. Rheumatoid arthritis shows a female-to-male ratio of roughly 5:1 in premenopausal women, and lupus reaches an astonishing 10:1. Neutrophils from premenopausal women display a more mature and responsive phenotype than male neutrophils, with a correspondingly greater propensity for NET formation, and estrogen itself can drive this pro-NETotic behavior. That observation placed oral contraceptives squarely in the crosshairs of the Colorado team, led by Daniele Marcy and M. Kristen Demoruelle, because the pill commonly induces anovulation and thereby lowers total systemic estrogen exposure.

The researchers drew on the Studies of the Etiology of Rheumatoid Arthritis, or SERA, an observational project running since 2005 that follows first-degree relatives of people with established RA alongside healthy community controls. From stored plasma samples, the team assembled three groups of premenopausal women: a derivation cohort of 77 healthy women, a validation cohort of 87 healthy women, and a cohort of 104 women at elevated risk for RA because a first-degree relative had the disease. All participants completed detailed questionnaires on contraceptive, pregnancy, and smoking histories, and blood was drawn in EDTA tubes, processed within 30 minutes, and stored at minus 80 degrees Celsius until batch testing.

To gauge NETosis, the team measured plasma calprotectin, a heterodimer of the alarmin proteins S100A8 and S100A9 that are highly abundant in the neutrophil cytoplasm and released during NET formation. Calprotectin is a well-established marker of neutrophil activation and correlates with inflammation in NET-associated diseases, and because it can be quantified with a widely available commercial ELISA kit, the assay offers low inter-assay variability and a plausible path into routine clinical care. Importantly, the researchers excluded anti-CCP-positive individuals, since ACPA can independently induce NETosis and would muddy the interpretation. Laboratory technicians were blinded to each sample’s contraceptive status.

The results were strikingly consistent. Among healthy women in the derivation cohort, current pill users had a mean calprotectin level of 0.99 micrograms per milliliter compared with 1.38 in never or prior users, a difference that reached statistical significance at p equals 0.016. The validation cohort reproduced the pattern, with 0.9 versus 1.4 micrograms per milliliter and a p value of 0.001. In the at-risk relatives, current users again measured lower, at 1.19 versus 1.74 micrograms per milliliter, p equals 0.017. In multivariable linear regression models adjusting for age, ever smoking, and ever pregnancy—variables previously linked to NET levels—the association held, with borderline significance in the derivation cohort and a highly significant result in the validation cohort, where pill users averaged 0.56 micrograms per milliliter less calprotectin. Among the at-risk women, the adjusted difference was 0.73 micrograms per milliliter.

Notably, the effect did not appear to accumulate over time. There was no correlation between calprotectin levels and the duration of pill use, nor between calprotectin and the years elapsed since discontinuation among prior users. The authors argue this fits a model in which OCP-induced anovulation suppresses the high peri-ovulatory estradiol peaks that push neutrophils toward a NET-prone phenotype, an effect that begins shortly after initiation and reverses quickly upon stopping. When the team could confirm formulations through medical chart review, all 36 women documented were taking low-dose estradiol preparations of 0.035 milligrams or less, and estradiol dosage itself showed no correlation with calprotectin levels.

The numbers also sit sensibly within known biology. Mean calprotectin among healthy never or prior pill users, around 1.4 micrograms per milliliter, falls toward the upper end of the typical published range of 0.1 to 1.5, while the at-risk cohort’s never users averaged a modestly elevated 1.74. By contrast, patients with active rheumatoid arthritis commonly show calprotectin levels in the range of 10 to 50 micrograms per milliliter, underscoring that the study captured differences in a healthy or very early at-risk state rather than florid inflammation. The choice of EDTA-preserved plasma rather than serum also matters, since clotting during serum generation can activate neutrophils ex vivo and artificially inflate measured calprotectin.

The authors are careful about what the study can and cannot claim. As a cross-sectional analysis, it demonstrates association, not causation, and calprotectin release is not exclusive to NETosis—neutrophil necrosis and degranulation can also contribute. The team did not directly measure estradiol levels or confirm ovulatory status with luteinizing hormone surges, and no participants developed clinical RA during follow-up, precluding direct assessment of whether reduced NETosis actually mediates the lower RA risk previously reported in pill users. Still, multiple epidemiologic studies, including the Swedish EIRA study, have linked oral contraceptive use to reduced RA risk and to lower positivity for rheumatoid factor, and the new data offer a candidate mechanism: dampening NET formation and the citrullinated antigens it generates during a critical window of immune priming.

Future work, the researchers say, should extend these observations to women with established RA and lupus, examine neutrophil function before and after pill initiation in vivo, and test whether other hormonal contraceptives differing in estrogen dose, formulation, and route of administration produce similar effects. The study was funded by the National Institutes of Health and the University of Colorado Anschutz Ludeman Family Center for Women’s Health Research, and it appears in Frontiers in Lupus. If confirmed longitudinally, the findings could reframe a daily pill taken by millions as an unexpected modulator of innate immunity—one that may quietly influence which women’s neutrophils never fire their traps at all.

Subject of Research: Immunology

Article Title: Oral contraceptive pill Use is associated with lower levels of plasma calprotectin in premenopausal women

Article References: Marcy, D., Maretz, C., Sturm, K., Lugo, C., Deane, K. D., Holers, V. M., Norris, J. M., Zell, J., & Demoruelle, M. K. (2026). Oral contraceptive pill Use is associated with lower levels of plasma calprotectin in premenopausal women. Frontiers in Lupus, 4, Article 1819508. https://doi.org/10.3389/flupu.2026.1819508

Image Credits: AI Generated

DOI: 10.3389/flupu.2026.1819508

Keywords: oral contraceptives, calprotectin, NETosis, neutrophil extracellular traps, rheumatoid arthritis, lupus, autoimmune disease, estrogen, premenopausal women, immunology, women's health, biomarkers

The review was led by Andrea Romanos-Nanclares, PhD, of the Channing Division of Network Medicine within the Department of Medicine at Mass General Brigham, with A. Heather Eliassen, ScD, of Mass General Brigham and the Harvard T.H. Chan School of Public Health serving as senior author. To capture the full scope of the studies’ contributions, the team used a database to identify and review relevant publications covering research from 1984 to 2026, supplemented by papers from the authors’ own files. They then synthesized findings across the three cohorts that make up the enterprise: the original Nurses’ Health Study, Nurses’ Health Study II and Nurses’ Health Study 3.

What sets these studies apart from traditional research designs is their prospective structure. Rather than asking women to recall past behaviors after illness strikes, the studies have followed large populations of nurses for decades, repeatedly measuring diet, lifestyle, reproductive factors, medications and environmental exposures along the way. This design allows researchers to examine not only whether certain exposures are associated with disease, but also how the timing, duration and changes in those exposures influence health across the entire life course. The cohorts have continually incorporated new technologies, biospecimens, biomarkers and statistical methods, keeping the science at the cutting edge as analytical tools have evolved.

Among the most consequential findings highlighted in the review is the role of dietary trans fats in coronary heart disease. Evidence from the Nurses’ Health Studies showed that these industrially produced fats substantially increase heart disease risk, a discovery that helped inform the U.S. Food and Drug Administration’s ban on industrial trans fats. It is a striking example of how long-term observational research, carefully conducted, can drive regulatory change with global implications for cardiovascular health.

The studies have also delivered sobering news about meat consumption. Higher intake of red and processed meat has been associated with increased risk of type 2 diabetes, colorectal cancer, cognitive decline and dementia. These findings fed into international evaluations by the World Health Organization and the International Agency for Research on Cancer, including the classification of processed meat as a carcinogenic hazard. Beyond individual foods, the research demonstrated that overall dietary patterns matter more than any single nutrient: diets rich in fruits, vegetables, whole grains, legumes, nuts and unsaturated fats are associated with lower risks of cardiovascular disease, cancer and premature mortality.

Perhaps the most empowering message to emerge from five decades of data concerns modifiable lifestyle factors. Combinations of healthy diet, healthy weight, regular physical activity and not smoking are associated with markedly lower risks of coronary heart disease and type 2 diabetes, as well as a greater likelihood of healthy aging. The same healthy behaviors, the research shows, can influence cardiovascular health, diabetes risk, cancer outcomes, cognitive health and longevity simultaneously. Prevention, in other words, is not about dodging one disease at a time; it is a unified strategy with cascading benefits across the body.

Reproductive and hormonal factors have been a central thread throughout the studies’ history. Because the original cohort was assembled specifically to investigate oral contraceptives, the research has accumulated unmatched evidence on how contraceptive use and menopausal hormone therapy affect women’s health across the life course. This evidence has informed clinical guidelines from major medical organizations, including American Heart Association recommendations on cardiovascular health and American Diabetes Association guidance on diabetes prevention, shaping the advice clinicians give patients every day.

The review also emphasizes what the studies have revealed about cancer survivorship, an area of growing importance as more people live with and beyond a cancer diagnosis. For those already diagnosed, the research suggests that what happens after diagnosis matters profoundly. Physical activity after diagnosis, for example, has been associated with lower mortality across several cancer types. The goal, the authors note, is to translate long-term population research into information that supports both prevention and more comprehensive survivorship care, giving patients and clinicians actionable evidence for the period when quality of life and long-term outcomes are most at stake.

Methodological evolution has been as important to the studies’ success as their sheer duration. From repeated dietary measurements in the early decades to metabolomics, proteomics, microbiome research and wearable technologies in recent years, the cohorts have adopted each new wave of scientific tools, allowing researchers to ask increasingly complex questions about how lifestyle and biology interact over the long term. This adaptability means the studies are not merely a historical archive of twentieth-century women’s health; they remain a living platform for twenty-first-century discovery, capable of integrating molecular data with decades of behavioral records.

For Romanos-Nanclares, the work carries a deeply personal dimension. She describes the opportunity to study factors that may help prevent breast cancer and improve the lives of women who are diagnosed as especially meaningful, noting that breast cancer is a personal disease for so many people. The Nurses’ Health Studies allow researchers to examine potentially modifiable factors both before and after diagnosis, offering women evidence-based ways to reduce their risk or live longer and healthier lives after a diagnosis. As the studies enter their second half-century, that combination of scientific rigor and human purpose continues to define their legacy: proof that following the same group of dedicated women for fifty years can change what the world knows about health, and what individuals can do to protect their own.

Subject of Research: Longitudinal cohort research on diet, lifestyle and chronic disease in women's health

Article Title: Research Spotlight: What the Nurses’ Health Studies have illuminated about women’s health over the past five decades

Article References: Research Spotlight: What the Nurses’ Health Studies have illuminated about women’s health over the past five decades. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Nurses' Health Studies, women's health, longitudinal cohort, diet, trans fats, cardiovascular disease, type 2 diabetes, cancer prevention, survivorship, oral contraceptives, healthy aging, epidemiology

The rationale for the study rests on a convergence of two clinical realities. First, the psychological burden of polycystic ovary syndrome is well documented in the literature. Women with the syndrome carry elevated rates of depression and anxiety compared with matched controls, and the distress is not merely a reaction to cosmetic concerns. Insulin resistance, obesity, chronic anovulation, and hyperandrogenism all contribute to a metabolic and endocrine milieu that researchers have increasingly linked to mood disorders. Earlier work, including a study by Sivayoganathan and colleagues published in Human Fertility, found that full investigation of patients presenting with polycystic ovary syndrome across four different clinical specialties revealed significant differences in morbidity and a troubling rate of undiagnosed disease, underscoring how often the syndrome’s systemic dimensions slip through the cracks of specialty-based medicine.

Second, the treatments themselves have plausible and, in some cases, documented effects on mood. Spironolactone, a potassium-sparing diuretic that blocks aldosterone and antagonizes androgen receptors, has become a mainstay of hormonal acne therapy in dermatology clinics, particularly for women whose acne flares along the jawline and resists conventional antibiotics and topicals. But the drug’s pharmacological reach does not stop at the sebaceous gland. A double-blind, placebo-controlled trial by Wang and colleagues in the mid-1990s found that spironolactone improved symptoms of premenstrual syndrome, suggesting a direct or indirect effect on the neuroendocrine pathways that govern cyclical mood changes. More recently, an observational case series by Wernze and Herdegen reported long-term benefits of spironolactone on pain, mood, and quality of life in women with fibromyalgia, hinting that the drug’s central nervous system effects may be broader than its dermatological reputation implies.

Oral contraceptives occupy an equally complicated position in this conversation. Combined formulations containing ethinylestradiol and anti-androgenic progestins such as drospirenone or dienogest are approved or widely used for acne, and they work by suppressing ovarian androgen production and increasing sex hormone-binding globulin, thereby reducing free testosterone. Yet the psychiatric profile of hormonal contraception has been the subject of intense public and scientific debate, with large pharmacoepidemiological studies over the past decade examining associations between contraceptive use and subsequent depression diagnoses, particularly in adolescents. A 2025 study by Palacio-Cardona and colleagues in the International Journal of Women’s Dermatology specifically assessed the contribution of a low-dose ethinylestradiol and dienogest combination to acne improvement and its perceived psychological effects in young university women, reflecting growing interest in whether clearing the skin translates into measurable psychological benefit.

Against this backdrop, the Drexel team asked a deceptively simple question: when patients with polycystic ovary syndrome-associated acne are treated with spironolactone, oral contraceptives, or the combination, what happens to their psychiatric outcomes? To answer it, the researchers turned to TriNetX, a federated health research network that aggregates de-identified electronic health record data from large numbers of healthcare organizations, primarily in the United States. TriNetX has become an increasingly popular tool for retrospective cohort studies because it allows investigators to define cohorts using standardized diagnostic and procedural codes, apply inclusion and exclusion criteria, and compare outcomes between exposed and unexposed groups across a dataset far larger than any single institution could provide. The platform’s scale is both its greatest strength and the source of its characteristic limitations, since the underlying data reflect real-world clinical documentation rather than the controlled conditions of a prospective trial.

The retrospective cohort design deserves attention in its own right. Rather than randomizing patients to treatment arms, the investigators identified patients with the relevant diagnoses and exposures in the historical record and compared psychiatric outcomes across treatment groups. This approach captures clinical reality, including the prescribing patterns, comorbidities, and patient populations that never make it into randomized trials, but it also introduces the perennial challenge of confounding. Patients who receive spironolactone may differ systematically from those who receive oral contraceptives in age, contraceptive intent, disease severity, metabolic profile, or baseline psychiatric history, and any of these differences could influence downstream mental health outcomes independently of the drugs themselves. Propensity matching and covariate balancing, the standard tools for mitigating such bias in database studies, become essential to interpreting any observed differences between groups.

The study’s framing within dermatology is significant for a reason that extends beyond academic taxonomy. Dermatologists prescribe a substantial share of the spironolactone and hormonal contraception used for acne, often as the sole prescriber managing these medications for patients whose underlying polycystic ovary syndrome may be undiagnosed or managed elsewhere, if at all. If these medications carry meaningful psychiatric effects, whether protective or adverse, the dermatology clinic becomes an unexpected frontline for mental health surveillance. Conversely, if clearing disfiguring acne produces measurable psychological improvement, that finding would strengthen the case for aggressive early treatment of a condition that is sometimes dismissed as merely cosmetic. The research letter, which the authors note was exempt from institutional review board oversight as a de-identified database study and was composed without the use of artificial intelligence, reflects a deliberate effort to bring quantitative evidence to a question that has largely been addressed through small studies, patient surveys, and clinical intuition.

It is worth being clear about what a study of this kind can and cannot establish. Retrospective database analyses identify associations within the recorded data; they cannot prove causation, and the psychiatric diagnoses captured in electronic health records depend on patients seeking care, clinicians documenting systematically, and coding practices that vary across institutions. The direction of any observed association is also vulnerable to reverse causation: patients whose mood deteriorates may be more likely to seek medical attention, receive new diagnoses, or have their records enriched with psychiatric codes, irrespective of any drug effect. These caveats are not reasons to dismiss the work but rather the essential context in which its findings must be weighed, and they explain why the authors frame the study as a contribution to an emerging evidence base rather than a definitive answer.

Nevertheless, the questions the study raises are timely and, for many patients, deeply personal. Online communities dedicated to polycystic ovary syndrome are filled with accounts of mood changes attributed to hormonal treatments, and clinicians routinely field questions about whether spironolactone causes depression or whether birth control pills will worsen anxiety. The scientific literature has offered only partial and sometimes contradictory guidance, with studies of individual drugs in different populations, at different doses, and with different outcome measures producing a patchwork that is difficult to translate into clinical advice. A cohort study that directly examines psychiatric outcomes in the specific population of polycystic ovary syndrome patients being treated for acne addresses precisely the population in which these questions arise most often in practice.

The Drexel study also fits into a broader movement within dermatology toward recognizing the specialty’s psychological dimensions. Acne vulgaris itself is associated with increased rates of depression, anxiety, and even suicidality, and the perceived psychological effects of acne treatment have become an explicit outcome in contemporary trials, as the Palacio-Cardona study demonstrates. As large-scale health data networks make it feasible to follow hundreds of thousands of patients across years of care, the field is gaining the statistical power to detect effects that smaller studies could only glimpse. Whether spironolactone and oral contraceptives ultimately prove to be psychiatrically neutral, protective, or harmful in this population, studies of this design represent the kind of evidence that will be needed to answer a question that matters to the millions of patients navigating both the skin and the mood consequences of polycystic ovary syndrome. The research letter, published as volume 318, article number 429 of the Archives of Dermatological Research, with no external funding and no relevant disclosures reported by the authors, is a compact but pointed addition to that effort.

Subject of Research: Psychiatric outcomes of hormonal acne treatments in polycystic ovary syndrome

Article Title: Psychiatric outcomes in PCOS-associated acne patients using spironolactone and/or oral contraceptives: a retrospective cohort TriNetX study

Article References: Curley, C., Wambold, D., & Ilyas, E. N. (2026). Psychiatric outcomes in PCOS-associated acne patients using spironolactone and/or oral contraceptives: a retrospective cohort TriNetX study. Archives of Dermatological Research, 318(1), Article 429. https://doi.org/10.1007/s00403-026-04896-x

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04896-x

Keywords: polycystic ovary syndrome, PCOS, acne, spironolactone, oral contraceptives, psychiatric outcomes, depression, anxiety, TriNetX, retrospective cohort study, dermatology, hormonal therapy

A new systematic review and meta-analysis published in BMC Cancer has now brought the weight of all available evidence to bear on that question, and its conclusions are both reassuring and subtly intriguing. Led by Mohammad Amouzadeh-Lichahi, Maryam Jafari, Nazila Sattari, Sara Zamani, Negin Letafatkar and Shahriar Ghodous of Guilan University of Medical Sciences in Rasht, Iran, the research team systematically searched PubMed, Scopus and Embase for observational studies published up to July 2026. Their exhaustive sweep of the literature identified twenty-seven reports that met their rigorous inclusion criteria, covering the use of oral contraceptive pills, menopausal hormone therapy, estrogen therapy alone, and combined estrogen–progestin therapy in relation to pancreatic cancer risk. By pooling adjusted effect estimates across studies with random-effects models, the team aimed to produce the most definitive statistical picture to date of how these hormonal exposures relate to one of oncology’s deadliest cancers.

The methodological machinery behind the analysis was considerable. The researchers followed PRISMA reporting guidelines and evaluated study quality using the Newcastle–Ottawa Scale, while the certainty of the resulting evidence was graded with the GRADE framework. Heterogeneity among studies was quantified with the I-squared statistic, and publication bias was probed with both Egger’s and Begg’s tests. Crucially, the team went beyond simple pooled estimates: they computed ninety-five percent prediction intervals, which indicate the range of effects that might plausibly be expected in a future study conducted in a new population, and they performed both linear and non-linear dose–response meta-analyses to test whether longer durations of hormone use translated into progressively altered risk. This layered approach matters because a pooled relative risk alone can mask enormous variability in what individual studies actually find.

The headline result for oral contraceptives was, in statistical terms, a null finding. Across twenty studies, women who had used the pill showed a pooled relative risk of pancreatic cancer of 0.99, with a ninety-five percent confidence interval spanning 0.86 to 1.14 — a range that comfortably includes no effect. The prediction interval was strikingly wide, stretching from 0.62 to 1.59, and heterogeneity between studies was substantial at 61.4 percent. The GRADE assessment rated this evidence as very low certainty. In plain language, the analysis found no overall association between oral contraceptive use and pancreatic cancer, but the underlying studies disagreed with one another enough that the true effect in any given population could conceivably fall anywhere between a meaningful reduction and a meaningful increase in risk.

Menopausal hormone therapy told a similar story. Drawing on eighteen studies, the pooled adjusted relative risk was 0.92, with a confidence interval of 0.79 to 1.06 that again crossed the threshold of no effect. Heterogeneity was even higher here, at 75.9 percent, and the prediction interval ranged from 0.54 to 1.56, once more signaling that results varied dramatically across populations and study designs. Estrogen therapy used alone, examined across six studies, yielded a pooled relative risk of 0.82 with a confidence interval of 0.63 to 1.07 — a point estimate hinting at a possible protective trend, but one that failed to reach statistical significance and was likewise graded as very-low-certainty evidence. For all three of these exposures, the adjusted analyses simply did not support a consistent link with pancreatic cancer.

The one exception emerged with estrogen–progestin therapy, the combined form of menopausal hormone therapy in which estrogen is paired with a progestin to protect the uterine lining. Across five studies, this regimen was associated with a modest but statistically robust inverse association: a pooled relative risk of 0.85, with a tight confidence interval of 0.78 to 0.93 and, remarkably, zero heterogeneity among the contributing studies. The prediction interval of 0.77 to 0.94 mirrored that consistency. This was the only finding in the adjusted analyses to achieve statistical significance, and it was graded as low-certainty evidence — a notch above the very-low ratings given to the other exposures, but still short of the certainty clinicians would want before drawing firm conclusions.

The biology behind such a signal is not far-fetched. Pancreatic ductal adenocarcinoma, the dominant form of the disease, expresses estrogen receptors and the G protein-coupled estrogen receptor, and experimental work has implicated estrogen signaling in pathways central to cancer cell behavior, including the PI3K/AKT and MAPK cascades, insulin-like growth factor signaling, and inflammatory and oxidative stress processes. Progestins, meanwhile, can modulate cell proliferation and differentiation. A modest protective effect of combined estrogen–progestin therapy is therefore biologically plausible, even if the observational nature of the evidence and the small number of contributing studies demand caution. Confounding by indication, differences in body mass index, smoking status, diabetes prevalence and other lifestyle factors across study populations could all shape the observed associations in ways that statistical adjustment cannot fully remove.

Indeed, the secondary crude analyses illustrated exactly how fragile such associations can be. When the researchers pooled unadjusted effect estimates instead of adjusted ones, they found substantially lower odds of pancreatic cancer among oral contraceptive users (an odds ratio of 0.70) and estrogen–progestin users (an odds ratio of 0.55). But both of these crude analyses were plagued by substantial heterogeneity and wide prediction intervals — the estrogen–progestin prediction interval stretched from 0.16 to 1.97 — suggesting that the apparent protection in crude data may partly reflect confounding by factors such as socioeconomic status, healthcare access, or healthier baseline profiles among hormone users rather than a genuine biological effect. The divergence between crude and adjusted results is a textbook demonstration of why observational hormone epidemiology is so treacherous.

The dose–response analyses added a further layer of nuance. Neither oral contraceptive use nor menopausal hormone therapy showed a significant linear relationship with pancreatic cancer risk per five-year increase in duration of use: the relative risks were 1.07 (p = 0.158) for the pill and 0.84 (p = 0.128) for menopausal hormone therapy. Non-linear models likewise failed to identify any significant threshold or U-shaped pattern. In other words, there was no evidence that taking hormones for longer periods progressively shifted risk in either direction, which weakens the case for a strong causal relationship and suggests that any real effects, if they exist, are likely to be modest and context-dependent.

The authors’ conclusions are measured and appropriately cautious. The adjusted evidence did not show a consistent association between oral contraceptive, menopausal hormone therapy, or estrogen therapy use and pancreatic cancer risk, and although estrogen–progestin therapy was linked to a modest reduction in risk, that finding rests on low-certainty observational evidence from only five studies. The wide prediction intervals for oral contraceptives and menopausal hormone therapy indicate that associations may vary across populations and settings, and the team explicitly calls for further large prospective studies to clarify the long-term hormonal effects on pancreatic carcinogenesis. For the millions of women weighing the risks and benefits of hormonal medications, the practical takeaway is largely reassuring: nothing in this comprehensive synthesis suggests that these widely used therapies meaningfully raise the risk of pancreatic cancer. And for researchers, the modest inverse signal from combined therapy offers a tantalizing, testable hypothesis — one that could ultimately illuminate how estrogen and progestin signaling shapes one of medicine’s most lethal tumors.

Subject of Research: The association between oral contraceptive and menopausal hormone therapy use and pancreatic cancer risk

Article Title: Oral contraceptive and menopausal hormone therapy use and risk of pancreatic cancer: a systematic review, meta-analysis, and dose–response analysis

Article References: Amouzadeh-Lichahi, M., Jafari, M., Sattari, N., Zamani, S., Letafatkar, N., & Ghodous, S. (2026). Oral contraceptive and menopausal hormone therapy use and risk of pancreatic cancer: a systematic review, meta-analysis, and dose–response analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16902-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16902-6

Keywords: pancreatic cancer, oral contraceptives, menopausal hormone therapy, estrogen therapy, estrogen–progestin therapy, meta-analysis, systematic review, dose–response analysis, observational studies, exogenous hormones, BMC Cancer, cancer epidemiology